Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SCD | O00767 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5706569 | 0.83 | HSD11B1 (0.41) | LMNAHSD11B1MEN1KMT2APTGER4 | |
| SCHEMBL5759297 | 0.81 | CCR5 (0.44) | KDM4EHSD11B1PTGER4CCR5 | |
| SCHEMBL10726480 | 0.77 | HTR2A (0.59) | LMNASCDKDM4EHSD11B1 | |
| SCHEMBL10722254 | 0.77 | HTR2A (0.59) | LMNASCDKDM4EHSD11B1 | |
| SCHEMBL10722200 | 0.77 | HTR2A (0.59) | LMNASCDKDM4EHSD11B1 | |
| SCHEMBL10587794 | 0.76 | ALDH1A1 (0.46) | LMNAKDM4EHSD11B1MEN1KMT2A | |
| SCHEMBL8669709 | 0.76 | DRD2 (0.56) | KDM4EMEN1KMT2A | |
| SCHEMBL5172227 | 0.76 | KDM4E (0.64) | KDM4E | |
| SCHEMBL7410657 | 0.75 | PTGER4 (0.54) | KDM4EPTGER4 | |
| Hydrochloric Acid SCHEMBL28203039 | 0.74 | KCNK3 (0.51) | LMNAHSD11B1PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080268-A1 | Process of preparing O-carbamoyl compounds in the presence of active amine group | SK CORPORATION (KR) | 2005-04-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080268-A1 | Process of preparing O-carbamoyl compounds in the presence of active amine group | CBR3, ARG1, ODC1 | LMNA 3459/4885SCD 1328/4885KDM4E 631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.